Joe Rogan Experience #2469 - Brigham Buhler
In a Nutshell
Brigham Buhler details ongoing efforts with the new HHS/FDA leadership under Kennedy to reclassify peptides, debunk testosterone-prostate cancer myths, and create regulatory pathways for peptides, stem cells (especially Muse cells), and compounding pharmacies, countering Big Pharma lobbying that protects patents and stifles proactive, cash-pay healthspan medicine. He critiques the chronic disease-focused U.S. healthcare system—highest spending, worst outcomes—and advocates state-level actions (Texas, Florida) plus a parallel "life raft" model using AI, genetics, DEXA scans, and therapies like plasma feresis for personalized prevention over symptom treatment. Key wins include HHS removing hormone black box warnings; Muse cells emerge as a safe, pluripotent breakthrough for regeneration, outperforming traditional MSCs in homing, safety, and results for injuries, neurodegeneration, and longevity.
These notes were generated by AI and may contain inaccuracies.
Joe Rogan mentions having allergies, sounding stuffed up, initially thinking he might be sick but feeling great physically after working out. They discuss environmental factors in Austin like cedar pollen, which affected Rogan severely when he first moved from Houston (pine trees there). Body adapts over time. Brigham recommends colostrum daily for allergies; consistency makes a big difference.
Brigham updates on administration working to reclassify peptides, unveiled on Rogan's podcast with Secretary Kennedy a few weeks ago. Labor of love for 2.5-3 years. Most optimistic ever with reason. Prior FDA administration classified peptides as dangerous like a Trojan horse before Kennedy's team took over. Submitted 17 FOIA requests to FDA for clarity on safety and decisions; no responses despite legal requirement. Now have seat at table with accessibility.
Kennedy uses peptides, knows benefits, is fit and educated. Millions use them for improved health and vitality; both Rogan and Brigham are users.
Brigham was typical American patient: on cusp of diabetes, obese former fat kid in late 30s, trusted system with annual blood work but declined due to systemic issues. Peptides nuanced for FDA legacy employees. Thanks to new administration, meetings with Stephanie Spear (Kennedy's right-hand), Marty Makary (FDA head, book Blind Spot), testified together at Senate. Makary open-minded, admits not intimate with peptides as surgeon but willing to research.
HHS moves on testosterone and hormone therapy match what they discussed 5 years ago: debunked dogma, no cancer risk, remove black box warnings, counter women's health initiative fear-mongering. Hormonal decline in 40s-50s drives health decline; hormones crucial for health span.
Rogan asks to expand on testosterone due to friends' prostate cancer concerns. Recommends checking levels, TRT, or hCG to increase testosterone for vitality.
Fear from 1930s study by urologist: 3 patients, 1 dropped out, 1 chemically castrated (zero testosterone), 1 normal. Raising from zero to normal (e.g., 0 to 350) theoretically risks exacerbating pre-existing prostate cancer during climb, but optimal levels insulate against multiple cancers. No study correlates testosterone therapy to prostate cancer. Some urologists cautious post-radical prostatectomy.
Analogy: saturate prostate receptor sites like watering a plant; excess provides cancer reduction benefits.
FDA under new leadership removing black box warnings on hormones.
Initial study: chemically castrated patient had concern during rise; normal patient no risk. Must push past threshold for benefits.
Real-world: testosterone boom should skyrocket prostate cancer if risk real, but prevalence same (1 in 8 men). Everyone dies with some prostate cancer (per Huberman).
1930s conclusion: treating with testosterone raises precursor hormone risking prostate cancer.
Debunked in 1990s by Dr. Morgansteller (urologist) treating prostate cancer patients with HRT, no increased prevalence or exacerbation.
Pfizer launched testosterone cream ~1990s; millions used, no issue. Retrospectively, 100 years later, FDA changing lens on men’s and women’s HRT.
Doctors still caution due to medical school dogma perpetuated as urban legend. Admiral Brian Christine (FDA men's health, urologist) uses testosterone. Makary covers in Blind Spot. Quote from book: confusing dogma with consensus; group think is peer pressure, not true consensus.
Peptides backlash tied to system built for big pharma: $1-3 billion to bring drug to market (including failures; true cost $300M-$1B). Protects patents, limits innovation under safety guise.
Naysayers: no human trials/safety data on peptides. Provided FDA 800+ studies on 19 banned peptides. 90,000+ patients at Waistwell used them safely, no adverse events.
Peptides are proactive/preventative/personalized cash-pay medicine, not seeking Medicare/Medicaid/Tricare/employer coverage. Doesn't fit big pharma moat around chronic disease monetization.
Peptides/stem cells in no man's land, convicted without crime because don't fit sandbox.
GLP-1s are peptides; huge market (celebrities/influencers losing weight, e.g., Oprah, Ozempic face). Clinicians prescribe off-label routinely.
COVID example: hydroxychloroquine, ivermectin interfered with pharma profits.
Peptides backlash from GLP-1 weight loss drugs lobbying. 19 peptides banned without explanation.
Big pharma (Eli Lilly, Novo) lobbies: spent billions, compounders/independent pharmacies rip off patents. Chris Clump (FDA) negotiated most favored nation pricing.
Truth: NIH (taxpayer-funded) does much innovation/phase 1; pharma licenses.
FDA signaled shortage/backlog, allowed compounding (30-40 year pathway). Compounders met demand.
Eli Lilly 7x value to $800B (bigger than most nations); biggest blockbuster ever, money made 50,000x over.
Compounding sector $7B total; GLP-1s $2.5B during shortage (now less); shut down 503Bs (half capacity). Net $1.5-2B to meet needs vs. pharma's $35-40B this year (accounting error).
Dangerous precedent if pharma reclassifies all as biologics, extending patents 10
Big pharmaceutical companies extend patents for 10 to 12 years through a shell game, setting dangerous precedents. Shutting out compounders from making peptides risks them targeting the next therapy. Eli Lilly claims peptides are dangerous due to APIs from China and lack of regulation by compounders, yet signed a $7 billion deal to acquire a peptide company from China. This hypocrisy confuses regulators and the public, especially non-healthcare experts.
Big pharma spent $31 million on lobbying last year. Dollars buy access, which leads to impressionability and skewed outcomes. It's like debating where one side gets one minute to debunk nine minutes of skewed facts. Pharma claims $7 billion cost to bring drugs to market (cooking books by ignoring failed drugs and NIH-originated ones they monetized), warns of unsafe Chinese imports, triggering politician concerns amid campaign funding. Truth: recalls from Eli Lilly and Novo Nordisk, FDA data shows 60-80% of approved drugs get major label changes or recalls.
Anti-depressants required label changes for suicidal ideation in teenagers; they're barely better than placebo, far inferior to exercise (6-7x more efficacious). Science linking depression to serotonin was never proven—industry dogma. Marty Makary discusses this in his book.
Peptides enable proactive, predictive, preventative care for optimization/healing, not chronic disease symptoms. Current system monetizes symptom treatment via prescription management, not health. Regulators may not grasp this shift. Post-COVID, public questions FDA authority—FDA-approved doesn't mean safe, unapproved doesn't mean dangerous. BPC-157 has a Croatian patent expiring in three years; naturally occurring short-chain amino acid hard to patent. Big pharma patents GLP-1 dosing/delivery, sues over advertising, not patents themselves.
If only pharmaceutical companies made peptides, they'd become legal, creating a giant business with skyrocketing availability and TV ads (e.g., BPC-157 for soft tissue injuries, showing fit people jogging). Prices would rise but access explode.
- Traditional sick care system (insurance, big pharma, regulators): Led to 1.7-1.9 million annual U.S. chronic disease deaths (more than all world wars), most obese/diseased society ever, highest healthcare spending.
Chronic disease ignores politics; prevent/delay via proactive care, not symptom whack-a-mole. Insurance blocks diagnostics; system excels at catastrophic triage (heart attacks, strokes) but fails prevention/healthspan.
Future: AI, genetic sequencing, bloodwork, biomarkers, DEXA, VO2 max tracked real-time from 30s to predict/prevent disease years early (e.g., 40s cancer starts in 30s, diabetes in 30s from 20s issues). Prevent via diet/lifestyle/nutrition. Americans average 4+ prescriptions; can't prescribe out of obesity/epidemic.
Primary care (6-min visits, limited tests) pushes statins/GLP-1s/antidepressants for overweight/depressed patients. Longevity clinics run diagnostics: depression often hormonal imbalance (obesity ↔ hormones bidirectional). Jelly Roll example: Fixed insulin, hormones, estrogen, inflammation first for wins, not instant GLP-1 barrage.
Cash-pay splits: Elite concierge ($100k+/year, 99.99% can't afford); pill mills like Hims monetizing meds/peptides, not solving problems—mirrors big pharma.
Vision: Affordable, scalable concierge care driving healthspan. Issue is archer (motives), not arrow. Patient-first: Use AI/wearables for real-time tracking. App-integrated scale (1-2% DEXA variability) measures lean/fat/visceral/subcutaneous fat, BMI, cross-referenced with clinic DEXA/VO2 max.
Bloodwork just one marker; future affordable for all. Load any bloodwork (PCP, Hims, Function Health) for nuanced guidance—help patients leverage data.
If you help that person, they tell the world.
Businesses prioritize shareholders/profits over people (money above all evil). Waste to Well prioritizes patients (Denise as patient advocate/Jiminy Cricket). Growth challenges: Can't onboard 20k overnight; critics compare to others. Hims: BlackRock-backed multibillion marketing firm, not compounding clinics/biologics innovators.
Epiphany: AI/tools secondary; people first. Clinician relationships matter—dedicated employees, not hourly telemed hoppers (Monday babies, Tuesday testosterone).
Hims Super Bowl ad used Novo Nordisk's GLP-1 brand name (illegal for compounders—must use generic, no direct-to-consumer marketing like patented brands). Triggered backlash (politicians railed against compounders infringing patents/black market). Week later: Hims inks sole-source deal with Novo; stock soars. Designed Trojan horse to damage compounders after securing pharma deal. Told Kennedy admin: Don't punish industry for one bad actor (multibillion firm no accident). Class action/antitrust lawsuit by Lee Rosebush (pharmacist/lawyer, ex-Mayo Clinic) investigating.
Sunset provisions mean no one's going to pay attention. What's left for the rest of the industry? It's a slippery slope. Separate from peptides and compounds, there's the world of biologics, the future of biologics, stem cells, and creating a regulatory pathway. Secretary Kennedy tweeted before or right when he took over: "Save your bag. Save your records and pack your bags. Your war on stem cells and peptides are over." From meetings with the FDA, there's a more nuanced lens: they're navigating a nightmare regulatory landscape with lobbying power, impressions, half-baked truths. The system is built on getting a drug approved at billions of dollars cost, locking in patents, letting companies make money because they innovated, getting it on insurance formularies, Medicare, Medicaid, and Tricare.
Shelf peptides for a second and consider stem cell therapy. Mission is to build a life raft, like Henry Ford said: "If we would have asked clients what they wanted, they would have said a faster horse." Not going to the FDA saying, "Guys, how do we solve this problem?" The FDA has enough problems managing the current system. Build a life raft parallel to the existing one, like Uber did with taxis—let them drag race to see who prevents chronic disease better.
Well, the problem is it killed taxis.
Question is which model is better for humanity and takes cost out of the system. Tell regulators, congressmen: model costs nothing, no taxpayer dollars, no insurance billing. Ask federal government to trust the sacred relationship of clinician and patient, allow patient sovereignty and autonomy over health. Example: Brett Favre with advanced Parkinson's—why wait 10 years for FDA approval if something could change or save his life today, with means to pay and clinician who has an answer to slow or improve chronic disease progression? Government shouldn't stand in the way.
Reality: momentum of current healthcare system is strong; vast majority of Americans will use it anyway. It won't completely disrupt—most people trust their doctor, do what they've always done, unaware, business as usual, companies still grow. They're greedy, want all of it. Saying they're losing $7 billion—how much did you make?
[54:01] Sponsor: Athletic Brewing non-alcoholic beer has won 185 global taste awards, various styles like Goldens, IPAs, light brews, new lime and salt. Available at 75,000+ grocery stores, liquor stores, bars, restaurants, or online at athleticbrewing.com/rogan with code rogan for 15% off first order.
Big Pharma not losing anything. Give bad facts to politicians: "Oh my god, they cost you $7 billion." But they made $800 billion, 7xed company, Novo Nordisk 3-4xed in three years. Richest companies, patents worked, prevented others from taking pie—arguably worked too well. Overregulating based on that is wrong.
Argument for compounders to make patient-specific GLP-1s: allow patients to titrate up and titrate down, avoid catastrophic muscle wasting. Patients with allergies, backlogs, can't handle delivery mechanism—dozens of reasons for alternative life raft.
Titrate up and down: Historically, GLP-1s in preset dosages; no way to titrate. Clinicians used compounding pharmacies for micro-dosing flexibility. Catastrophic side effects from large doses. Now, most compounding shut down for GLP-1s; 503Bs (bulk) banned from making weight loss drugs. Limited to 503As (patient-specific, personalized). Heyday maybe $2 billion for whole industry vs. $800 billion company—everyone's okay. Patients had accessibility, affordability. Big Pharma's battlecry misleading without nuances.
Issues: accessibility, black market. People buy peptides online not what they say—e.g., CJ Corman (likely CJ C-19 or similar) has physiological flushing response; online stuff often doesn't work. Told Marty McCary at FDA and Chris Clump this message. They're receptive. For peptides: Chris, Marty, Stephanie Spear, Bobby aligned—peptides done, matter of when. Huge win, goes bigger.
Preventative longevity medicine close to being shut down if compounders gone, FBI at black/gray market doors. If Kennedy not secretary and MAGA movement hadn't started, over. If Kamala Harris wins, totally over. In Texas, Congresswoman Lacy Holes, Senator Kohurst (healthcare committee) considered Texas FDA. States hedging against restrictive federal guidelines.
To Marty: Naysayers say grandfathering peptides is wild west. But today is most dangerous time in peptide history—cat's out of bag, patients tasted efficacy, won't stop. 4 out of 5 peptides filled via gray/black market, no clinician in chain of custody. Eli Lilly/Novo's $7 billion loss mostly black market, not even all real. Large percentage off, sometimes 2x dosed—risks muscle wasting, catastrophic events due to lack of regulation. Black market claims non-human use loophole.
Call with prominent peptide company CEO (Ivy League): Claims safe, legal opinions, but uses influencers for human use while labeling non-human. Warned: DOJ will subpoena, uncover circumvention. Happened 8 months later—FBI at gray/black facilities, 100% because of Retatrutide (Eli Lilly's triple agonist, hits 3 receptor sites, less muscle wasting, better safety, substantial fat loss; not through phase 3, not available). FDA letter: illegal for compounders to make.
Compounding pharmacies inspected: FDA in building 5 times in 4 years, states every year in 47 states. Third-party verify dosages, buy API (Active Pharmaceutical Ingredients) from FDA green list. No checks in gray/black market.
Scarier: online buys no doctor, clinic, blood work; drop-shipped, no dosing instructions, reconstitution explanation (teaching = medical administration). Used ChatGPT, but now shut down. No guidance, oversight, clinician, regulators—wild west.
Fix: Restore pre-Biden administration status—peptides back to trained clinicians, pharmacists, compounding pharmacies under guidelines. Peptides safe (200 naturally occurring in body, raw elements in nature). Focus: sterility, efficacy, safety—minimize via checks.
Overnight fix makes big Pharma ecstatic—eliminates 4/5 weight loss drugs without clinician. Argument against: lack robust human trials. Counter: 60-80% drugs get major label changes post-approval. 90% operating room products via 510K process, no human safety studies—off-label common.
Most dangerous now with no checks. Pathway provides affordability, accessibility, personalized medicine, predictive care—saves industry. Owning clinic, telemedicine: can't work without quality products. Change allows safe, quality products with checks, sets up for stem cells.
Reasonable: cut black market, regulate stem cells/peptides/compounding—everybody wins. Pharma wants only them to win; any compounding profit is stolen.
Like food lobby testimony for SNAP/school lunch—align with new food pyramid, real food. States faster: Texas passed 3 bills on food initiatives, labels, protecting children; Arizona, Florida followed—creates trade wind for federal.
Working Texas state level for peptides, then biologics/stem cells for healthspan, prevent chronic disease. Texas Compassionate Use Act: chronic disease patients have right to try. If clinic manufactures/compounds in-state, can administer in-state despite FDA stance (like marijuana).
Utah, Florida did this. Testified in Arizona two weeks ago on stem cell bill (Senator Jana Champ)—passed House, likely Senate. States move faster, build safety nets for patient access.
Submitted citizens petition to FDA mirroring Florida law: stem cells safe, adverse events minimal (10-15%, flu-like). Major issues from improper chain of custody—fix with regulation, clinician involved. Provides affordable, accessible, safe care while FDA works insurance later.
Don't want insurance model—castrates decisions. Example: purified amnion for burn victims/wound management; orthopedic surgeons billed as wounds for ACL—insurance fraud, created counterculture against stem cells. Decade ago, now none covered, no FDA indication, gray area.
Peptides are used in practices every day throughout the country and are now legal in states like Texas, Florida, Arizona, and soon Utah. Secretary Kennedy, Chris Clump, and Marty are open-minded and receptive. Marty covers challenges in his book. Optimism for federal peptide approval, followed by citizens petition for biologics to make them affordable and accessible.
And the thing that's helping the momentum I think is that so many people know people that have had stem cell treatment and have had amazing results like with injuries that they just couldn't recover from.
Some had to go to Panama, Tijuana, Colombia where it's legal. Many people with injuries consider going to Tijuana. Personal contacts like dad, uncle, grandma had results unachievable otherwise.
Senator Cohurst and Representative Lacy Hole will get it done in Texas with a new bill in January expanding patient right to choose legislation to hedge against big pharma power. Confident in this administration, but state-level sovereignty crucial against future changes and lobbying.
Florida saw $300 million infusion from becoming a medical tourism destination. Opportunity for Texas to do the same with food bill and MAHA movement for longevity and preventative care, turning Texas into medical tourism destination. People would visit Austin confidently without needing a passport.
People go to Panama because desperate. Easier to fly Southwest to Austin.
Wealthiest country, sickest country, highest healthcare spending, most messed up. Appeal to authority resists radical change despite experts messing up: 60-80% of drugs get major label changes or removed, known adverse effects.
Not conspiracy to keep people fat and sick maliciously, but system born broken with special interests influencing accessibility and affordability, catastrophic effects on health and national security. 71% of young kids can't qualify for military service. Average American can't do two pull-ups; Secretary Kennedy does 20+ at 70.
System extracts enormous money; profitable to keep as is. Can be profitable with workable model benefiting people.
Build cash pay model as life raft for preventative healthcare instead of perpetual sick care leading to side effects.
Peptides optimize: personal example of DHEA improving neurocognitive function, data recall, retention; doctor-prescribed, cash-paid, no need for others' approval. Safety important, but FDA efficacy approval is multi-billion dollar process for set-it-and-forget-it insurance model (e.g., Lipitor yearly check).
Cash pay: educated patient fires clinician if no wins; integrity via consumer market, unlike insurance where you can't fire clinician.
Regulators claim vertical integration issue (own pharmacy and clinics), but patient right to take prescription anywhere. Compete on price, quality, efficacy, cost; if not, go elsewhere.
Insurance model controls doctors and pharmacies via PBMs, rebates, monetizes chronic disease. Cash model drives health span; patients become willing participants feeling good (mental, cognitive, physical, skin).
Example: Jelly lost weight from 500 lb, now runs 5 miles, bow hunts, hobbies; continues peptides knowingly.
Track via DEXA, VO2 max, wearables, vertically integrated real-time, aggregate across population. Dream: 10-15 million patients; e.g., P452 gene marker on testosterone improves REM sleep.
Need peptides, biologics, diagnostics like comprehensive blood work. Gene sequencing: <1 in 1,000 people sequenced; only 1 in 1,000 animals. Genetics in infancy.
Example: Helping Gordon Ryan. Mentors: Chief Science Officer Ian White (22 years stem cell research, Harvard, Sabri Stem Cell Institute), Mari Dezawa (discovered muse cells, Japan, stem cell pioneer), Dr. Deutscher (Stanford, stem cell/longevity), Ryan Rosner PhD (DARPA).
Next app version: simplicity, refills, vertical pharmacy integration. AI chatbot Allen pulls medical records, charts, consult notes for questions.
Scale concierge medicine cheaply via large language models and AI.
Add gene sequencing: 20,000 genes. Genes are software running biology. Ryan Rosner (DARPA geneticist): era of real-life X-Men; gene editing injection makes bone mineral density 8x stronger (illegal in US; China/Russia pushing). Changes BMI, DEXA readings.
Mutation example: bones 8x denser but can't swim.
Gordon Ryan gene sequencing: 1 in 10 million gene for denser, resilient tendons; higher bone mineral density propensity. Downside: predisposition to staph (weakened immune), acidic gut health causing infections, gut biome issues in wrestling environment. Achilles heel despite athletic advantages.
Automate genetics knowledge via AI in app with VO2 max, DEXA, blood work (any source). Predictive, personalized medicine.
Blood work is snapshot affected by variables; DEXA can't lie (visceral/subcutaneous fat, organ fat, atrophy differences).
Liam Harrison DEXA: more muscle on bum knee leg than strong leg despite overcompensation.
Data blueprints: quantify bone loss, fracture risks (vertebral, hip), preserve via hormones.
Unorthodox thinking, cash pay model as life raft for healthspan to prevent chronic disease (Secretary Kennedy's legacy goal). Optimize to superhuman: optimal hormones, bone density vs normal.
If genetic issue found, explains repetitive problems for tailored treatments. Future: turn genes on/off like switch.
Whales have unique protein for 200+ year lifespan; synthesize for human healthspan/longevity.
The premise is synthesizing and utilizing a gene to turn it on in humans, enabling secretion and production of higher levels of a specific protein or amino acid to drive health span and reduce cancer risk. As science evolves, the question is which genes can be turned on or off. China and Russia are already doing this. In a decade, people will look back in disbelief at using petrochemicals to solve problems when genes can be toggled at the cellular level to fix issues. Bone mineral density treatments turn on a gene to increase density. Follistatin used in cattle turns on a gene signal for muscle growth over 6-12 months, then turns off like a temporary light switch.
Jamie, bring up the bone mineral density info. High bone mineral density (HBM) causes excess sinking when swimming due to increased body density and weight, similar to French bulldogs and English bulldogs that drown because they lack arm strength, muscle mass, short legs, and can't move their dense body composition effectively. Pit bulls can swim. Little Carl is jacked but might not like the pool; he's a tank and smart. Marshall is soft and swims like a fish for hours. A Frenchie loves water but stays in the shallow end, smart enough not to leave the step.
Individuals with unexplained HBM had excess sinking when swimming (adjusted odds ratio 7.1136, 95% confidence). Associated with skeletal dysplasia. Study on high bone density shows sinking is more difficult due to heaviness and density. Denser bodies like Brian Shaw's (bone mineral density 1 in 500 million, maybe 8-10 people on Earth) sink like a rock; genetics and strongman training contribute. Devon Lorette's gene sequencing shows statistically impossible genes: same tendon gene, bone mineral density gene, unique genes suggesting he was built in a lab.
Genes are inherent from birth, but epigenetics are impacted by activity. Predisposition to cancer doesn't mean it will develop; lifestyle changes like not smoking minimize risk. For weak bone mineral density predisposition, prevent hormone decline in 40s.
LRP5 gene variants interfere with eye blood vessel development, causing familial exudative vitreoretinopathy leading to vision loss. Mutations range from asymptomatic high bone density to severe skeletal fragility or blindness.
Muse stem cells are the most exciting development in healthcare. Approached by a company about a subtype of stem cell, vetted by chief science officer Dr. White, then flew to Japan in September to meet Mari Dezawa, tour her lab, and review research since 2010. Went to debunk but left convinced: if real, it changes regenerative medicine. Ian (20 years stem cell research, regenerative scientist of the year in North America) agreed.
Muse stands for Multilineage-differentiating Stress Enduring cells (<2% of stem cells). Mari discovered them in 2010: left them on a petri dish overnight after sushi and sake, expected them dead, but most survived, sparking research.
Traditional MSCs (mesenchymal stem cells) are safe; Dr. Kaplan apologized for calling them stem cells as they don't differentiate in the body, only signal damage, transfer mitochondria temporarily for healing, but don't become tissues. Pros: non-tumorigenic. Cons: not truly regenerative.
Muse cells are naturally pluripotent (can become anything) yet non-tumorigenic. In studies, never formed tumors, even shrank pre-existing tumors in mice. Safer than traditional MSCs (0% flu-like symptoms vs. 10-15%). Immunomodulate: mice accepted sutured human livers temporarily.
During pregnancy, MSCs prevent immune rejection of the fetus (foreign body), reducing mom's inflammation, chronic disease, cancer risk, all-time low mortality.
Used in plastic surgery (Dubai) with fat transfers to promote angiogenesis, tissue acceptance, reduce rejection.
Multi-lineage means pluripotent: like a kindergartener who can become anything (doctor, astronaut). Traditional MSCs are "grown up" with fixed identity.
Muse cells home to damage via phagocytosis (Pac-Man): gobble damaged cell (e.g., neuron), take its characteristics, become young healthy version. Happens in 3 days.
Traditional MSCs: 3-5% engraftment. Muse: 15-30%, half the size, pass lungs intravenously, heat-seeking to S1P/SP1 inflammation signals.
Available in Florida, Texas, Arizona. Hope for federal pathway. 30-40 years data shows MSCs safe, natural. FDA concerns claims due to snake oil, but accessibility key for terminal patients, neurocognitive issues (pierce midbrain). Studies on Ways to Well website (7-8 of Mari Dezawa's).
Muse cells decline with age: abundant at birth, less in 30s, nonexistent in 40s-50s. Also absent in diabetics due to chronic inflammation. Dr. Dominic Dürschner (Germany, Stanford/Harvard/University of Munich, 14 years stem cell research) identified absent subset in diabetics, realized it was Muse after meeting Mari.
One IV bag reduced mitochondrial age by 1.5 years.
Muse cells show extreme mitochondrial benefits in studies, leading to phenomenal results in treatments. Still a proponent of traditional modalities with miraculous results, but Muse cells represent the holy grail. Mari discovered them in 2010, human use started in 2019. Used daily in Dubai and overseas; people fly there paying big dollars for treatments.
Son of a UAE sheikh in car wreck, hospital declared him brain-dead, ready to harvest organs. Dominic contacted hospital and German scientists for call with Mari. Treated with intravenous Muse cells; kid in coma, nonresponsive, neurologists said no brain function. Post-treatment, responding to mother, moving hands, no longer harvesting organs.
In Japan, treated children born with encephalitis. Untreated leads to neurocognitive issues, defects, mental retardation. Children treated with Muse within eight days of birth all had normal brain function.
Studies show benefits in hearts, myocardial infarctions, and more, with a decade of promising data not yet in US. Technologies to be adopted at state level, hopefully federal, with Secretary Kennedy opening regulatory pathways for stem cells; Muse as safer, more efficacious subset.
Exciting research emerging: gene therapies, Muse cells compounding. Ryan suggests taking Muse cell (can become anything, ready to learn), teach it to be specific (e.g., neuron), administer with pre-programmed commands.
Muse cells are resilient super soldier cells, stress-enduring. Mari's book chapter "Sake in Science": realized ultra-resilient nature through sake dinner insight. Ship at room temperature, viable for weeks vs. traditional cells needing cryopreservation and dry ice. Superior in administration, logistics, efficacy, safety.
Need US regulatory pathway for accessibility so Americans don't travel abroad. States acting, ideally federal post-states. Excited but cautious: science early, promising, no false hope. Success with traditional MSCs on orthopedic injuries (knees, shoulders, elbows) via mitochondria transfer. Muse cells differentiate, become broken cells for regeneration; sky's the limit.
Future questions pharmaceutical drugs when genetics, stem cells, biologics, LLMs, wearables enable real-time tracking. Resistance due to pharma money. Stem cells challenge: if ineffective, people won't pay. New administration plans pathways for peptides, stem cells, cash-pay products balancing safety.
Question multi-billion FDA process for non-patentable, safe, natural treatments; grandfather in for compassionate use in chronic diseases, death sentences. Traditional MSCs too big for blood-brain barrier; Muse cells intranasally administered, reach midbrain (Parkinson's, neurocognitive diseases). Trials: visible 18 months later. Promise for meaningful change at state level, already overseas; US regulatory lag frustrating given effective use abroad for hospital/chronic cases.
Dana White mentioned needing Mexico, but available in Austin, Texas at clinic (added 3 months ago). Over 50 years use at Mayo Clinic, academic institutions, now for longevity in cash-pay model. Run blood through dialysis machine, isolate/remove inflammatory markers, bad stuff from plasma.
For 45-year-old, removes 70% of 45 years attrition. Replace with young healthy albumin. At Ways to Well, stack with MSCs, peptides, cellular goodies declining with age. Like oil change for body. Studied 50+ years for inflammatory issues, Alzheimer's (inflammation-related).
Removes synthetic chemicals, BPCs, endocrine disruptors like bisphenol plasticizers, phthalates from ultra-processed food packaging (Dr. Shanna Swan's topics).
Philip Franklin Lee case: chronically tired, testosterone ~80-90. Microplastics test highest seen (eats sushi wrapped in plastic). Reduced via protocols, awareness (stopped plastic bottles). Testosterone now 1,200 without TRT. Inflammation/microplastics caused fatigue, immune issues, low T cascade.
Challenge: no claims, nuance like psychedelics FDA trials (integration therapy complicates billing/indications). Patients stack treatments (hocky, plasma feresis, MSCs for inflammation); works, but hard to isolate needle-mover vs. cumulative. Track single modalities better; patients want everything at once, report feeling phenomenal.
Thank yous: impactful discussion. Guest credits Rogan platform for meeting Secretary Kennedy, aiding navigation for peptides/stem cell accessibility amid opposition.
Keep PowerfulJRE in your library
Save the videos and channels worth coming back to, and find them again in one place.
